Abstract
We evaluated the use of a new, controlled-release capsule form of carbamazepine, Carbatrol capsules, in an open-label, multicenter study of 124 patients with complex partial seizures. Ninety-one percent of the patients successfully completed the 6-month trial with good seizure control, with a significant improvement in quality of life. We conclude that switching patients with complex partial seizures from multiple daily-dose carbamazepine to twice-daily Carbatrol on a milligram-to-milligram basis is relatively safe.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1727-1729 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 51 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1998 |
ASJC Scopus subject areas
- Clinical Neurology
Fingerprint Dive into the research topics of 'Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures'. Together they form a unique fingerprint.
Cite this
Mirza, W. U., Rak, I. W., Thadani, V. M., Cereghino, J. J., Garnett, W. R., Brown, L. M., Zhang, Y., & Belendiuk, G. W. (1998). Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology, 51(6), 1727-1729. https://doi.org/10.1212/WNL.51.6.1727